LONDON: Canopy Growth Corp has joined forces with a UK researcher of cannabis-based therapies after the British government moved to liberalise the use of medical marijuana.
The new company, formed with Beckley Canopy Therapeutics Ltd, aims to make products available in Britain from early this year. The government made it legal for specialist doctors to prescribe medical marijuana for patients with severe clinical need in November.
“We are witnessing the birth of the UK medical cannabis industry, an industry borne out of the un-met clinical needs of patients across the country,” said Marc Wayne, co-managing director of the venture, called Spectrum Biomedical UK.
The partnership “is testament to the importance of the opportunity to help patients access the medicine here in the UK,” he added in a statement.
The venture was created after Canopy, a Canadian giant of the cannabis industry, conducted clinical trials of marijuana-based drugs in the UK last year.
The company and its investors said they put £7.4mil (US$9.5mil) into testing products for treatment of pain and opioid dependence. — Bloomberg
Did you find this article insightful?